|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
|
30606076 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Instances of TP53 promoter methylation were observed only in a few samples of diffuse large B-cell lymphoma tissue.
|
30871527 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
|
31359442 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.
|
31187468 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Integration of bioinformatics and experiments to identify TP53 as a potential target in Emodin inhibiting diffuse large B cell lymphoma.
|
30096626 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma.
|
29512700 |
2018 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma.
|
28284458 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We studied P53 expression in 201 patients with untreated de novo diffuse large B-cell lymphoma.
|
27739436 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
|
29250662 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.
|
28484276 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results also provide insights into the regulation and function of p50 in diffuse large B-cell lymphoma and its cross talk with the p53 pathway with important therapeutic implications.
|
28281555 |
2017 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
TP53 dysfunction in diffuse large B-cell lymphoma.
|
26315382 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
|
27825110 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss-of-function mutations and copy number alterations in the tumor suppressors TP53 (diffuse large B-cell and follicular lymphoma), CDKN2A (diffuse large B-cell and marginal zone lymphoma), PTEN (diffuse large B-cell lymphoma), ATM (diffuse large B-cell lymphoma), and NF1 (diffuse large B-cell lymphoma), and gain-of-function mutations in the oncogenes HRAS (follicular lymphoma) and NRAS (diffuse large B-cell lymphoma) were also observed.
|
27102345 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Of those with the morphology of diffuse large B-cell lymphoma, the EBV-negative cases were more frequently TP53-mutated (P<0.001), p53 positive by immunohistochemistry (P<0.001), CD30 negative (P<0.01), and of germinal center immunophenotype (P=0.01) compared with EBV-positive cases.
|
27443517 |
2016 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
|
25284491 |
2015 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
|
26324762 |
2015 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
|
24722400 |
2014 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
|
23515929 |
2013 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.
|
22975378 |
2012 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
|
21394100 |
2011 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
|
21874232 |
2011 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
TP53 disruption (47.1%) and c-MYC abnormalities (26.2%) were the most frequent alterations, whereas common genetic lesions of de novo diffuse large B-cell lymphoma were rare or absent.
|
21266718 |
2011 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The TP53 72CC genotype was associated with increased risk of NHL (P 5 0.04) and diffuse large B-cell lymphoma (P 5 0.04).
|
20734458 |
2010 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study was conducted to analyze the frequency, expression patterns, and the impact of individual proteins BCL2, BCL6, and p53 on overall survival (OS) in adult, diffuse large B-cell lymphoma (DLBCL) patients.
|
20160358 |
2010 |